Interleukin-18 Inhibition Aggravates Atherosclerosis in Jak2 Clonal Hematopoiesis

Read full text
Authors: Mojdeh S. Tavallaie, Cheng-Chieh Hsu, Brian D. Hardaway, Huijuan Dou, Trevor P. Fidler, Eunyoung Kim, Sandra Schiavone, David Ngai, Tong Xiao, Nan Wang, Marit Westerterp, Alan R. Tall
Cited by: 3
References: 63

Abstract

Clonal hematopoiesis (CH) driven by JAK2V617F is known to accelerate atherosclerosis through inflammasome activation and release of interleukin (IL)-1β and -18; yet, the specific contribution of IL-18 has remained unclear. In this study, we demonstrate that antibody inhibition of IL-18 in JAK2V617F CH mice increases plaque collagen but paradoxically promotes both early lesion growth and advanced necrotic core formation. Mechanistically, IL-18 blockade reverses absent in melanoma 2 inflammasome activation but shifts cell death toward apoptosis, and together with impaired efferocytosis, results in greater necrosis. These events are coordinated by reduced interferon gamma signaling, which enhances collagen deposition while decreasing expression of efferocytotic genes. Our findings challenge the prevailing notion that IL-18 inhibition stabilizes atherosclerotic plaques and provide new mechanistic insight into the interplay among inflammasome biology, adaptive immunity, and plaque stability.

Fields of Study & Subjects

Inflammasome and immune disorders Myeloproliferative Neoplasms: Diagnosis and Treatment Cytokine Signaling Pathways and Interactions

Publication details

Journal / source
JACC Basic to Translational Science
Publisher
Elsevier BV
Volume
11
Issue
3
Pages
101463–101463
Publication date
25 February 2026
Language
EN